The optimal blood pressure target in old and very old patients with hypertension.

Background With the rise in older population globally, the optimal blood pressure (BP) target for antihypertensive therapy in those aged 60 and above remains to be evaluated in the real-world practice. This study evaluated the effectiveness and safety of standard versus lower BP targets in old (aged...

Descripción completa

Detalles Bibliográficos
Publicado en:Age & Ageing Vol. 55; no. 6; pp. 1 - 12
Autores principales: Zhang, Ran, Lam, Ivan Chun Hang, Liu, Xinyi, Sun, Feng, Zhan, Siyan, Yiu, Kai Hang, Chui, Celine Sze Ling, Chan, Esther Wai Yin, Wong, Ian Chi Kei, Lam, Cindy Lo Kuen
Formato: Artículo
Publicado: Oxford University Press / USA Jun2026
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=195099716&site=ehost-live
header:
  @attributes:
    shortDbName: ssf
    uiTerm: 195099716
    longDbName: Social Sciences Full Text (H.W. Wilson)
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        00020729
        AGA
      jtl: Age & Ageing
      issn: 00020729
      maglogo: N
    pubinfo:
      dt: Jun2026
      vid: 55
      iid: 6
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        195099716
        10.1093/ageing/afag167
      ppf: 1
      ppct: 11
      formats:
      tig:
        atl: The optimal blood pressure target in old and very old patients with hypertension.
      aug:
        au:
          Zhang, Ran
          Lam, Ivan Chun Hang
          Liu, Xinyi
          Sun, Feng
          Zhan, Siyan
          Yiu, Kai Hang
          Chui, Celine Sze Ling
          Chan, Esther Wai Yin
          Wong, Ian Chi Kei
          Lam, Cindy Lo Kuen
        affil:
          Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China
          Pharmaco- and Device Epidemiology, Health Data Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, United Kingdom
          Department of Epidemiology and Biostatistics, School of Public Health, Peking University, No. 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaKey Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, No. 38 Xueyuan Road, Haidian District, Beijing 100191, China
          Cardiology Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, No. 102 Pokfuam Road, Pokfulam, Hong Kong Special Administrative Region, ChinaCardiology Division, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, No. 1 Haiyuan First Road, Futian District, Shenzhen, ChinaThe Institute of Cardiovascular Science and Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, China
          School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, ChinaSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China
          Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, ChinaDepartment of Pharmacy, The University of Hong Kong-Shenzhen Hospital, No. 1 Haiyuan First Road, Futian District, Shenzhen, ChinaShenzhen Institute of Research and Innovation, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
          Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, ChinaAston Pharmacy School, Aston University, Birmingham, B4 7ET, United KingdomSchool of Pharmacy, Macau University of Science and Technology, Avenida Wii Long, Taipa, Macau Special Administrative Region, ChinaAdvanced Data Analytics for Medical Science (ADAMS) Limited, No. 19 Science Park West Avenue, Hong Kong Special Administrative Region, China
          Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, No. 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, ChinaDepartment of Family Medicine, The University of Hong Kong-Shenzhen Hospital, No. 1 Haiyuan First Road, Futian District, Shenzhen, China
      su:
        Hong Kong (China)
        Hypertension
        Aging
        Old age
        Cardiovascular disease prevention
        Risk assessment
        Statistical hypothesis testing
        Scientific observation
        Logistic regression analysis
        Major adverse cardiovascular events
        Antihypertensive agents
        Descriptive statistics
        Cardiovascular diseases risk factors
        Electronic health records
        Blood pressure
        Ambulatory blood pressure monitoring
        Data analysis software
        Confidence intervals
        Blood pressure measurement
        Sensitivity & specificity (Statistics)
        Nonparametric statistics
      sug:
        subj:
          Hypertension
          Aging
          Old age
          Hong Kong (China)
          All Other Miscellaneous Ambulatory Health Care Services
          Pharmaceutical and medicine manufacturing
          Cardiovascular disease prevention
          Risk assessment
          Statistical hypothesis testing
          Scientific observation
          Logistic regression analysis
          Major adverse cardiovascular events
          Antihypertensive agents
          Descriptive statistics
          Cardiovascular diseases risk factors
          Electronic health records
          Blood pressure
          Ambulatory blood pressure monitoring
          Data analysis software
          Confidence intervals
          Blood pressure measurement
          Sensitivity & specificity (Statistics)
          Nonparametric statistics
      keyword:
        adverse event
        aged
        antihypertension management
        antihypertensive agents
        blood pressure
        cardiovascular diseases
        chronic
        copyrightHolder:British Geriatrics Society
        copyrightYear:2026
        hong kong
        https://dx.doi.org/10.1093/ageing/afag167
        hypertension
        inLanguage:en
        kidney failure
        mortality
        older patients
        publisher:Oxford University Press
        safety
        sameAs:https://pubmed.ncbi.nlm.nih.gov/42258778/
        adverse event
        aged
        antihypertension management
        antihypertensive agents
        blood pressure
        cardiovascular diseases
        chronic
        copyrightHolder:British Geriatrics Society
        copyrightYear:2026
        hong kong
        https://dx.doi.org/10.1093/ageing/afag167
        hypertension
        inLanguage:en
        kidney failure
        mortality
        older patients
        publisher:Oxford University Press
        safety
        sameAs:https://pubmed.ncbi.nlm.nih.gov/42258778/
      ab: Background With the rise in older population globally, the optimal blood pressure (BP) target for antihypertensive therapy in those aged 60 and above remains to be evaluated in the real-world practice. This study evaluated the effectiveness and safety of standard versus lower BP targets in old (aged 60–79) and very old (aged ≥80) patients with hypertension in real-world clinical settings. Methods We emulated a target trial using electronic medical records from the Hong Kong Hospital Authority, including patients aged 60 years or above with a diagnosis of hypertension, uncontrolled BP and records of antihypertensives adjustments from 2008 to 2013. Patients were first categorized into 3 age groups (60–69, 70–79, ≥ 80) and then assigned to BP targets of either 130–140/80–90 mmHg or below 130/80 mmHg. Outcomes included major cardiovascular disease (CVD), end-stage renal disease, all-cause mortality and major adverse events related to antihypertensive treatment. Results Of 132 430 eligible patients identified, 52 553, 28 661 and 7106 patients aged 60–69, 70–79 and ≥ 80 years had BP targets of 130–140/80–90 mmHg, respectively; 11 148, 5636 and 1203 of patients in the same age groups had targets below 130/80 mmHg. Lower BP target was associated with reduced overall CVD and all-cause mortality: aged 60–69 years (CVD HR: 0.91 [95% CI, 0.85–0.96]; all-cause mortality: 0.89 [0.81–0.98]), aged 70–79 years (CVD: 0.87 [0.82–0.93]; all-cause mortality: 0.84 [0.78–0.91]), and aged≥80 years (CVD: 0.77 [0.69–0.86]; all-cause mortality: 0.80 [0.72–0.89]). No significant increase in major adverse events was observed in any age group. Results were consistent across all subgroups. Conclusion Lowering BP of below 130/80 mmHg in old and very old patients was associated with better cardiovascular and mortality outcomes without increased adverse events. These findings suggest that a lower BP target may be beneficial and safe for older patients with hypertension.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: N
    holdings:
      @attributes:
        islocal: N